Levetiracetam approved uses fda ema india?

Question

Accepted Answer

Levetiracetam (brand Keppra®) – Approved Indications by Major Regulators

Region	Authority	Indications (as of the latest approval)	Notes
United States	FDA	• Partial‑onset (focal) seizures – adjunctive therapy in adults and in patients ≥ 1 month old (children, adolescents, adults). • Myoclonic seizures – in juvenile myoclonic epilepsy (JME) as adjunctive therapy. • Generalized tonic‑clonic (GTC) seizures – adjunctive therapy in adults.	• FDA added the GTC indication in 2012 (and reaffirmed it in subsequent label updates). • Not approved for status epilepticus or for “first‑line” monotherapy.
European Union	EMA	• Partial‑onset seizures – adjunctive therapy in adults and in patients ≥ 1 month old. • Myoclonic seizures – in juvenile myoclonic epilepsy (JME).	• The EMA label does not list generalized tonic‑clonic seizures as an approved use (at least up to the most recent 2023 update).
India	CDSCO (Central Drugs Standard Control Organization)	• Partial‑onset seizures – adjunctive therapy in adults and in patients ≥ 1 month old. • Myoclonic seizures – in juvenile myoclonic epilepsy.	• India’s approval is essentially the same as the EU’s—no separate GTC indication.

Feature	FDA	EMA	India
Partial‑onset seizures	✔️ (adult & pediatric)	✔️ (adult & pediatric)	✔️ (adult & pediatric)
Myoclonic seizures (JME)	✔️	✔️	✔️
Generalized tonic‑clonic seizures	✔️ (adult)	❌	❌
Status epilepticus	❌	❌	❌
First‑line monotherapy	❌	❌	❌

Regulatory Strategy – The FDA sometimes expands indications after post‑marketing studies or new safety data (e.g., the GTC use). The EMA and Indian authorities often rely on the same pivotal trials, leading to slightly narrower approved indications.
Label Updates – If you’re looking at a very recent label (2024/2025), always check the latest updates. Some manufacturers have applied for new indications (e.g., GTC in the EU) that may not yet be reflected in the official dossier.
Geographic‑Specific Clinical Practice – In many countries, clinicians use levetiracetam off‑label for GTC seizures even if the official approval only lists partial‑onset and myoclonic seizures.

Check the local label: The exact wording can change with new data or regulatory decisions.
Consider the therapeutic context: Even if a use is not officially approved, it may still be clinically justified and covered under certain insurance policies, depending on local regulations.
Stay updated: Regulatory approvals can change; reviewing the FDA’s or EMA’s “Drug Repositioning” updates or the Indian CDSCO announcements is a good practice.

Let me know if you need more details on dosing, safety, or how these approvals impact specific patient populations!

Ask Questions, Get Industry Insights … Instantly